Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 1/2014

01-01-2014

A novel role for bioactive lipids in stem cell mobilization during cardiac ischemia

New paradigms in thrombosis: novel mediators and biomarkers

Authors: Prabhakara R. Nagareddy, Ahmed Asfour, Yuri M. Klyachkin, Ahmed Abdel-Latif

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2014

Login to get access

Abstract

Despite major advances in pharmacological and reperfusion therapies, regenerating and/or replacing the infarcted myocardial tissue is an enormous challenge and therefore ischemic heart disease (IHD) remains a major cause of mortality and morbidity worldwide. Adult bone marrow is home for a variety of hematopoietic and non-hematopoietic stem cells including a small subset of primitive cells that carry a promising regenerative potential. It is now well established that myocardial ischemia (MI) induces mobilization of bone marrow-derived cells including differentiated lineage as well as undifferentiated stem cells. While the numbers of stem cells carrying pluripotent features among the mobilized stem cells is small, their regenerative capacity appears immense. Therapies aimed at selective mobilization of these pluripotent stem cells during myocardial ischemia have a promising potential to regenerate the injured myocardium. Emerging evidence suggest that bioactive sphingolipids such as sphingosine-1-phosphate and ceramide-1-phosphate hold a great promise in selective mobilization of pluripotent stem cells to the infarcted region during MI. This review highlights the recent advances in the mechanisms of stem cell mobilization and provides newer evidence in support of bioactive lipids as potential therapeutic agents in the treatment of ischemic heart disease.
Literature
1.
Rosamond W et al (2008) Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25–e146CrossRefPubMed
2.
Braunwald E, Bristow MR (2000) Congestive heart failure: fifty years of progress. Circulation 102:14–23CrossRef
3.
4.
5.
Rupp S et al (2008) Characterization of long-term endogenous cardiac repair in children after heart transplantation. Eur Heart J 29:1867–1872CrossRefPubMed
6.
7.
Deb A et al (2003) Bone marrow-derived cardiomyocytes are present in adult human heart: a study of gender-mismatched bone marrow transplantation patients. Circulation 107:1247–1249CrossRefPubMed
8.
de Weger RA et al (2008) Stem cell-derived cardiomyocytes after bone marrow and heart transplantation. Bone Marrow Transpl 41:563–569CrossRef
9.
Hsieh PC et al (2007) Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 13:970–974PubMedCentralCrossRefPubMed
10.
11.
12.
Massa M et al (2005) Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105:199–206CrossRefPubMed
13.
Lev EI et al (2005) Circulating endothelial progenitor cells and coronary collaterals in patients with non-ST segment elevation myocardial infarction. J Vasc Res 42:408–414CrossRefPubMed
14.
Shintani S et al (2001) Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 103:2776–2779CrossRefPubMed
15.
Wojakowski W et al (2009) Mobilization of bone marrow-derived Oct-4 + SSEA-4 + very small embryonic-like stem cells in patients with acute myocardial infarction. J Am Coll Cardiol 53:1–9CrossRefPubMed
16.
Wojakowski W et al (2006) Mobilization of CD34(+), CD117(+), CXCR4(+), c-met(+) stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction. Eur Heart J 27:283–289CrossRefPubMed
17.
Abdel-Latif A et al (2010) Evidence of mobilization of pluripotent stem cells into peripheral blood of patients with myocardial ischemia. Exp Hematol 38(1131–1142):e1131CrossRef
18.
Fukuhara S, Tomita S, Nakatani T, Yutani C, Kitamura S (2005) Endogenous bone-marrow-derived stem cells contribute only a small proportion of regenerated myocardium in the acute infarction model. J Heart Lung Transpl 24:67–72CrossRef
19.
Loffredo FS, Steinhauser ML, Gannon J, Lee RT (2011) Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell 8:389–398CrossRefPubMed
20.
Kucia M et al (2007) Morphological and molecular characterization of novel population of CXCR4+ SSEA-4+ Oct-4 + very small embryonic-like cells purified from human cord blood: preliminary report. Leukemia 21:297–303CrossRefPubMed
21.
Kucia M et al (2006) A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 20:857–869CrossRefPubMed
22.
Liu R, Klich I, Ratajczak J, Ratajczak MZ, Zuba-Surma EK (2009) Erythrocyte-derived microvesicles may transfer phosphatidylserine to the surface of nucleated cells and falsely ‘mark’ them as apoptotic. Eur J Haematol 83:220–229CrossRefPubMed
23.
Zuba-Surma EK et al (2008) Morphological characterization of very small embryonic-like stem cells (VSELs) by ImageStream system analysis. J Cell Mol Med 12:292–303CrossRefPubMed
24.
Kucia MJ et al (2008) Evidence that very small embryonic-like stem cells are mobilized into peripheral blood. Stem Cells 26:2083–2092CrossRefPubMed
25.
Hattan N et al (2005) Purified cardiomyocytes from bone marrow mesenchymal stem cells produce stable intracardiac grafts in mice. Cardiovasc Res 65:293–295CrossRef
26.
Kawada H et al (2004) Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 104:3581–3587CrossRefPubMed
27.
28.
Shake J et al (2002) Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 73:1919–1925CrossRefPubMed
29.
Oswald J et al (2004) Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22:377–384CrossRefPubMed
30.
Silva G et al (2005) Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111:150–156CrossRefPubMed
31.
Jiang Y et al (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41–49CrossRefPubMed
32.
D’Ippolito G et al (2004) Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 117:2971–2981CrossRefPubMed
33.
Bonig H, Priestley GV, Oehler V, Papayannopoulou T (2007) Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. Exp Hematol 35:326–334PubMedCentralCrossRefPubMed
34.
Mobius-Winkler S et al (2009) Time-dependent mobilization of circulating progenitor cells during strenuous exercise in healthy individuals. J Appl Physiol 107:1943–1950CrossRefPubMed
35.
Wojakowski W, Tendera M (2005) Mobilization of bone marrow-derived progenitor cells in acute coronary syndromes. Folia Histochem Cytobiol 43:229–232PubMed
36.
Wojakowski W, Landmesser U, Bachowski R, Jadczyk T, Tendera M (2012) Mobilization of stem and progenitor cells in cardiovascular diseases. Leukemia 26:23–33CrossRefPubMed
37.
Paczkowska E et al (2009) Clinical evidence that very small embryonic-like stem cells are mobilized into peripheral blood in patients after stroke. Stroke 40:1237–1244CrossRefPubMed
38.
Lee HM et al (2010) Mobilization studies in complement-deficient mice reveal that optimal AMD3100 mobilization of hematopoietic stem cells depends on complement cascade activation by AMD3100-stimulated granulocytes. Leukemia 24:573–582PubMedCentralCrossRefPubMed
39.
Massberg S et al (2007) Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 131:994–1008PubMedCentralCrossRefPubMed
40.
Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL (2002) Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med 195:1145–1154PubMedCentralCrossRefPubMed
41.
42.
Peled A et al (1999) The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. J Clin Invest 104:1199–1211PubMedCentralCrossRefPubMed
43.
Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ (2001) Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 98:1289–1297CrossRefPubMed
44.
Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ (2003) Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 111:187–196PubMedCentralPubMed
45.
Seitz G, Boehmler AM, Kanz L, Mohle R (2005) The role of sphingosine-1-phosphate receptors in the trafficking of hematopoietic progenitor cells. Ann N Y Acad Sci 1044:84–89CrossRefPubMed
46.
Hanel P, Andreani P, Graler MH (2007) Erythrocytes store and release sphingosine-1-phosphate in blood. FASEB J 21:1202–1209CrossRefPubMed
47.
Ratajczak MZ et al (2010) Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 24:976–985PubMedCentralCrossRefPubMed
48.
Marquez-Curtis LA, Turner AR, Sridharan S, Ratajczak MZ, Janowska-Wieczorek A (2011) The ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes. Stem Cell Rev 7:590–607PubMedCentralCrossRefPubMed
49.
Christopherson KW 2nd, Hangoc G, Mantel CR, Broxmeyer HE (2004) Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305:1000–1003CrossRefPubMed
50.
Basu S, Ray NT, Atkinson SJ, Broxmeyer HE (2007) Protein phosphatase 2A plays an important role in stromal cell-derived factor-1/CXC chemokine ligand 12-mediated migration and adhesion of CD34+ cells. J Immunol 179:3075–3085PubMed
51.
Gazitt Y, Liu Q (2001) Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin’s lymphoma patients. Stem Cells 19:37–45CrossRefPubMed
52.
Kim CH et al (2012) Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia 26:106–116PubMedCentralCrossRefPubMed
53.
Greenbaum AM, Link DC (2011) Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 25:211–217CrossRefPubMed
54.
Pusic I, DiPersio JF (2010) Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells. Curr Opin Hematol 17:319–326CrossRefPubMed
55.
McQuibban GA et al (2001) Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 276:43503–43508CrossRefPubMed
56.
McQuibban GA et al (2002) Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100:1160–1167PubMed
57.
Pelus LM, Bian H, King AG, Fukuda S (2004) Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 103:110–119CrossRefPubMed
58.
Boath A et al (2008) Regulation and traffic of ceramide-1-phosphate produced by ceramide kinase: comparative analysis to glucosylceramide and sphingomyelin. J Biol Chem 283:8517–8526CrossRefPubMed
59.
Sciorra VA, Morris AJ (2002) Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim Biophys Acta 1582:45–51CrossRefPubMed
60.
Long J et al (2005) Regulation of cell survival by lipid phosphate phosphatases involves the modulation of intracellular phosphatidic acid and sphingosine-1-phosphate pools. Biochem J 391:25–32CrossRefPubMed
61.
Mechtcheriakova D et al (2007) Sphingosine-1-phosphate phosphatase 2 is induced during inflammatory responses. Cell Signal 19:748–760CrossRefPubMed
62.
Schwab SR et al (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309:1735–1739CrossRefPubMed
63.
Brindley DN, English D, Pilquil C, Buri K, Ling ZC (2002) Lipid phosphate phosphatases regulate signal transduction through glycerolipids and sphingolipids. Biochim Biophys Acta 1582:33–44CrossRefPubMed
64.
Yatomi Y, Ozaki Y, Ohmori T, Igarashi Y (2001) Sphingosine-1-phosphate: synthesis and release. Prostaglandins 64:107–122PubMed
65.
Kihara A, Igarashi Y (2008) Production and release of sphingosine-1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta 1781:496–502CrossRefPubMed
66.
Venkataraman K et al (2006) Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J 397:461–471CrossRefPubMed
67.
Lamour NF et al (2007) Ceramide kinase uses ceramide provided by ceramide transport protein: localization to organelles of eicosanoid synthesis. J Lipid Res 48:1293–1304CrossRefPubMed
68.
Takuwa Y (2002) Subtype-specific differential regulation of Rho family G proteins and cell migration by the Edg family sphingosine-1-phosphate receptors. Biochim Biophys Acta 1582:112–120CrossRefPubMed
69.
Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4:397–407CrossRefPubMed
70.
Ishii I, Fukushima N, Ye X, Chun J (2004) Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 73:321–354CrossRefPubMed
71.
Hla T (2004) Physiological and pathological actions of sphingosine-1-phosphate. Semin Cell Dev Biol 15:513–520CrossRefPubMed
72.
Jo E et al (2005) S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol 12:703–715CrossRefPubMed
73.
Walter DH et al (2007) Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 27:275–282CrossRefPubMed
74.
Michaud J, Im DS, Hla T (2010) Inhibitory role of sphingosine-1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol 184:1475–1483PubMedCentralCrossRefPubMed
75.
Gomez-Munoz A, Kong JY, Salh B, Steinbrecher UP (2004) Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J Lipid Res 45:99–105CrossRefPubMed
76.
Granado MH et al (2009) Ceramide-1-phosphate (C1P) promotes cell migration Involvement of a specific C1P receptor. Cell Signal 21:405–412CrossRefPubMed
77.
Ryan MA et al (2010) Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med 16:1141–1146CrossRefPubMed
78.
Lindorfer MA et al (2010) A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115:2283–2291CrossRefPubMed
79.
Ohkawa R et al (2008) Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann Clin Biochem 45:356–363CrossRefPubMed
80.
81.
Whetton AD, Lu Y, Pierce A, Carney L, Spooncer E (2003) Lysophospholipids synergistically promote primitive hematopoietic cell chemotaxis via a mechanism involving Vav 1. Blood 102:2798–2802CrossRefPubMed
82.
Ryser MF, Ugarte F, Lehmann R, Bornhauser M, Brenner S (2008) S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34+ hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing. Mol Immunol 46:166–171CrossRefPubMed
83.
Golan K et al (2012) S1P promotes murine progenitor cell egress and mobilization via S1P1-mediated ROS signaling and SDF-1 release. Blood 119:2478–2488CrossRefPubMed
84.
Tesio M et al (2011) Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood 117:419–428CrossRefPubMed
85.
Dar A et al (2011) Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 25:1286–1296CrossRefPubMed
86.
Brinkmann V (2004) FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J 45:991–997PubMed
87.
Karapetyan AV et al (2013) Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev 22:1645–1656CrossRefPubMed
88.
Wu W et al (2011) The bone marrow-expressed antimicrobial cationic peptide LL-37 enhances the responsiveness of hematopoietic stem progenitor cells to an SDF-1 gradient and accelerates their engraftment after transplantation. Leukemia 26(4):736–745PubMedCentralCrossRefPubMed
89.
Wysoczynski M et al (2009) Defective engraftment of C3aR-/- hematopoietic stem progenitor cells shows a novel role of the C3a-C3aR axis in bone marrow homing. Leukemia 23:1455–1461PubMedCentralCrossRefPubMed
90.
Ratajczak J et al (2004) Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 103:2071–2078CrossRefPubMed
91.
Reca R et al (2003) Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood 101:3784–3793CrossRefPubMed
92.
Abdel-Latif A et al (2007) Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 167:989–997CrossRefPubMed
93.
Abdel-Latif A et al (2008) Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Am Heart J 156(216–226):e219
94.
95.
Nahrendorf M et al (2007) The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204:3037–3047PubMedCentralCrossRefPubMed
Metadata
Title
A novel role for bioactive lipids in stem cell mobilization during cardiac ischemia
New paradigms in thrombosis: novel mediators and biomarkers
Authors
Prabhakara R. Nagareddy
Ahmed Asfour
Yuri M. Klyachkin
Ahmed Abdel-Latif
Publication date
01-01-2014
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2014
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-013-1032-7

Other articles of this Issue 1/2014

Journal of Thrombosis and Thrombolysis 1/2014 Go to the issue

OriginalPaper

Targeting the host hemostatic system function in bacterial infection for antimicrobial therapies

OriginalPaper

Thrombin generation and atherosclerosis

OriginalPaper

Small cells, big effects: the role of platelets in transplant vasculopathy

OriginalPaper

New paradigms in thrombosis: novel mediators and biomarkers platelet RNA transfer

OriginalPaper

Emerging paradigms in arterial thrombosis

OriginalPaper

Modeling thrombin generation: plasma composition based approach
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits